KNSA
Kiniksa Pharmaceuticals, Ltd. NASDAQ Listed May 25, 2018$77.24
-2.63%
vs $79.33
Mkt Cap $5.9B
52w Low $35.20
88.1% of range
52w High $82.94
50d MA $74.06
200d MA $54.28
P/E (TTM)
73.0x
EV/EBITDA
50.8x
P/B
10.1x
Debt/Equity
0.0x
ROE
12.1%
P/FCF
240.1x
RSI (14)
47.60
ATR (14)
$2.47
Beta
0.06
50d MA
$74.06
200d MA
$54.28
Avg Volume
494.6K
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Clarendon House · Hamilton HM 11 · BM
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | BMO | 0.31 | 0.30 | -3.7% | 63.54 | +10.3% | +25.0% | +1.9% | -3.4% | -4.9% | -1.3% | — |
| Apr 28, 2026 | BMO | 0.18 | 0.27 | +50.0% | 53.85 | +0.1% | -1.6% | +1.5% | +2.8% | +4.3% | +0.0% | — |
| Feb 24, 2026 | BMO | 0.29 | 0.17 | -41.4% | 43.50 | +0.0% | -1.7% | +1.7% | +2.3% | +3.4% | -1.4% | — |
| Oct 28, 2025 | BMO | 0.33 | 0.23 | -30.3% | 39.43 | -0.4% | -5.2% | -0.2% | -0.8% | +1.2% | +2.9% | — |
| Jul 29, 2025 | BMO | 0.18 | 0.23 | +27.8% | 30.37 | +1.5% | -1.0% | +0.7% | +5.7% | +3.0% | +0.4% | — |
| Apr 29, 2025 | BMO | 0.02 | 0.11 | +450.0% | 25.88 | +0.5% | +4.2% | +2.9% | -0.3% | +0.5% | -3.0% | — |
| Feb 25, 2025 | BMO | -0.06 | -0.12 | -100.0% | 19.72 | +1.3% | -0.2% | -0.3% | +3.3% | +5.8% | -0.6% | — |
| Oct 29, 2024 | BMO | -0.02 | -0.18 | -662.4% | 23.27 | +0.1% | -1.1% | -1.8% | -0.5% | -4.4% | +2.6% | — |
| Jul 23, 2024 | BMO | -0.09 | -0.06 | +33.3% | 26.29 | -1.1% | -4.1% | +2.8% | +0.8% | +0.1% | +1.3% | — |
| Apr 23, 2024 | BMO | -0.14 | -0.25 | -78.6% | 17.68 | +3.0% | +1.0% | -1.4% | +1.5% | +3.7% | +0.9% | — |
| Feb 28, 2024 | BMO | -0.11 | 0.04 | +136.4% | 20.36 | +2.3% | +3.8% | +2.8% | -7.1% | -0.0% | +4.1% | — |
| Oct 31, 2023 | BMO | -0.18 | -0.20 | -11.1% | 15.25 | +0.7% | -0.7% | +5.4% | +1.6% | -0.4% | +2.4% | — |
| Jul 25, 2023 | TNS | -0.16 | -0.02 | +87.5% | 19.48 | +0.0% | +3.7% | -8.4% | +2.4% | -0.6% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29 | Wells Fargo | Maintains | Overweight → Overweight | — | $53.85 | $53.91 | +0.1% | -1.6% | +1.5% | +2.8% | +4.3% | -1.5% |
| Apr 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $53.85 | $53.91 | +0.1% | -1.6% | +1.5% | +2.8% | +4.3% | -1.5% |
| Apr 29 | Citigroup | Maintains | Buy → Buy | — | $53.85 | $53.91 | +0.1% | -1.6% | +1.5% | +2.8% | +4.3% | -1.5% |
| Apr 29 | Wedbush | Maintains | Outperform → Outperform | — | $53.85 | $53.91 | +0.1% | -1.6% | +1.5% | +2.8% | +4.3% | -1.5% |
| Apr 28 | Jefferies | Maintains | Buy → Buy | — | $43.61 | $47.20 | +8.2% | +23.5% | -1.6% | +1.5% | +2.8% | +4.3% |
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $45.89 | $46.44 | +1.2% | -1.2% | -0.9% | -5.4% | -0.0% | +1.4% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $43.50 | $43.50 | +0.0% | -1.7% | +1.7% | +2.3% | +3.4% | -1.4% |
| Feb 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $43.50 | $43.50 | +0.0% | -1.7% | +1.7% | +2.3% | +3.4% | -1.4% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $41.12 | $41.55 | +1.0% | -6.1% | +2.5% | -4.1% | +3.9% | +4.1% |
| Oct 29 | Goldman Sachs | Maintains | Buy → Buy | — | $39.43 | $39.29 | -0.4% | -5.2% | -0.2% | -0.8% | +1.2% | +2.9% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $38.92 | $38.90 | -0.1% | -0.7% | +0.9% | -0.4% | +0.1% | -0.3% |
| Oct 13 | Wedbush | Maintains | Outperform → Outperform | — | $37.89 | $38.21 | +0.8% | -2.3% | +2.3% | +2.6% | +0.2% | -0.7% |
| Sep 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $36.09 | $35.96 | -0.4% | -1.6% | +2.8% | +6.2% | +0.2% | -0.5% |
| Jul 29 | Jefferies | Maintains | Buy → Buy | — | $27.04 | $30.60 | +13.2% | +12.3% | -1.0% | +0.7% | +5.7% | +3.0% |
| Jul 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $27.21 | $27.71 | +1.8% | +5.8% | +0.5% | -3.0% | +2.5% | -2.5% |
| Apr 29 | Jefferies | Maintains | Buy → Buy | — | $21.47 | $22.55 | +5.0% | +20.5% | +4.2% | +2.9% | -0.3% | +0.5% |
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $21.22 | $21.00 | -1.0% | -3.2% | -1.6% | -0.8% | -0.1% | +4.3% |
| Nov 5 | JP Morgan | Maintains | Overweight → Overweight | — | $21.48 | $20.66 | -3.8% | +2.6% | +4.5% | -0.1% | -0.7% | +0.8% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $23.27 | $23.30 | +0.1% | -1.1% | -1.8% | -0.5% | -4.4% | +2.6% |
| Jul 23 | Wedbush | Maintains | Outperform → Outperform | — | $21.39 | $23.25 | +8.7% | +22.9% | -4.1% | +2.8% | +0.8% | +0.1% |
| May 1 | JP Morgan | Maintains | Overweight → Overweight | — | $18.72 | $18.81 | +0.5% | +3.6% | -0.1% | +3.6% | -0.4% | +1.7% |
| Apr 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $17.68 | $18.21 | +3.0% | +1.0% | -1.4% | +1.5% | +3.7% | +0.9% |
| Jan 2 | Wedbush | Maintains | Outperform → Outperform | — | $17.54 | $17.61 | +0.4% | +5.6% | +7.8% | -4.3% | -4.3% | +4.5% |
| Jul 26 | Goldman Sachs | Maintains | Buy → Buy | — | $19.48 | $19.48 | +0.0% | +3.7% | -8.4% | +2.4% | -0.6% | +0.3% |
| Mar 9 | JP Morgan | Maintains | Overweight → Overweight | — | $12.58 | $12.83 | +2.0% | -2.6% | -2.1% | -2.6% | -3.3% | +1.2% |
| Dec 29 | BofA Securities | Maintains | Buy → Buy | — | $12.13 | $12.07 | -0.5% | -0.2% | -1.2% | -1.7% | +5.1% | -5.4% |
| Apr 1 | BofA Securities | Maintains | Buy → Buy | — | $15.48 | $15.46 | -0.1% | -2.6% | +11.7% | +6.4% | -0.7% | -4.0% |
| Mar 11 | JP Morgan | Maintains | Overweight → Overweight | — | $17.96 | $17.75 | -1.2% | -10.4% | -6.8% | +3.4% | -24.4% | +5.7% |
| Dec 6 | Goldman Sachs | Upgrade | Neutral → Buy | — | $9.97 | $11.54 | +15.7% | +6.4% | +7.2% | +13.6% | -1.0% | +1.3% |
| Aug 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $11.10 | $10.46 | -5.8% | -3.7% | -12.0% | +6.2% | +4.0% | +1.1% |
| Mar 11 | Barclays | Maintains | Overweight → Overweight | — | $15.93 | $16.20 | +1.7% | +4.0% | +2.2% | +3.8% | +0.3% | -0.7% |
| Dec 12 | Wedbush | Maintains | Outperform → Outperform | — | $24.38 | $25.05 | +2.7% | +0.4% | -6.5% | -3.8% | -7.4% | -0.5% |
| Sep 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $26.48 | $27.85 | +5.2% | +5.7% | -1.5% | +6.3% | +5.5% | -3.8% |
| Jun 18 | Wedbush | Maintains | Outperform → Outperform | — | $18.29 | $18.30 | +0.1% | -4.3% | +8.6% | +7.1% | -5.4% | -0.2% |
| Jun 18 | JP Morgan | Maintains | Overweight → Overweight | — | $18.29 | $18.30 | +0.1% | -4.3% | +8.6% | +7.1% | -5.4% | -0.2% |
| Jun 18 | Goldman Sachs | Maintains | Neutral → Neutral | — | $18.29 | $18.30 | +0.1% | -4.3% | +8.6% | +7.1% | -5.4% | -0.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 21,097 | $54.04 | $1.1M | 65,623 | +2.63% | +1.90% |
| May 1, 2026 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 37,327 | $53.52 | $2.0M | 86,720 | +2.63% | +1.90% |
| May 1, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 48,565 | $54.02 | $2.6M | — | +4.25% | +2.93% |
| Apr 30, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 2,141 | $54.01 | $116K | — | +2.77% | -2.23% |
| Apr 29, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 22,544 | $54.01 | $1.2M | — | +2.77% | -2.23% |
| Apr 28, 2026 | Quart Barry D | — | Sell | 13,099 | $50.10 | $656K | 12,546 | +1.49% | +2.63% |
| Apr 28, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 51,750 | $54.02 | $2.8M | — | +2.77% | -2.23% |
| Apr 28, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 243,596 | $52.02 | $12.7M | 51,750 | +2.77% | -2.23% |
| Apr 28, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 113,673 | $51.47 | $5.9M | 295,346 | +2.77% | -2.23% |
| Apr 28, 2026 | Patel Sanj K | CHAIRMAN & CEO | Sell | 74,635 | $50.43 | $3.8M | 409,019 | +2.77% | -2.23% |
8-K · 2.02
!! High
Kiniksa Pharmaceuticals, Ltd. -- 8-K 2.02: Earnings Results
Kiniksa Pharmaceuticals reported Q2 2026 financial results, with detailed performance metrics available in the attached press release exhibit for investor review.
Jul 28
8-K
Kiniksa Pharmaceuticals, Ltd. -- 8-K Filing
May 29
8-K · 1.01
!! High
Kiniksa Pharmaceuticals, Ltd. -- 8-K 1.01: Material Agreement
May 26
8-K
Kiniksa Pharmaceuticals International, plc Class A -- 8-K Filing
Kiniksa Pharmaceuticals reports strong Q1 2026 results with continued ARCALYST revenue growth in recurrent pericarditis, demonstrating successful market expansion five years post-launch of their IL-1 inhibitor therapy.
Apr 28
8-K
Kiniksa Pharmaceuticals International, plc Class A -- 8-K Filing
Kiniksa Pharmaceuticals reported 2025 financial results and portfolio progress, with management hosting a conference call to discuss fourth-quarter performance and commercial advancements in cardiovascular therapies.
Feb 24
Institutional (13F) — Top 0
All ↗
No 13F holders found.
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$5.89B
Enterprise Value
$5.69B
P/E (TTM)
72.98x
Forward P/E
56.79x
PEG Ratio
-0.22x
P/B
10.10x
P/S
7.00x
P/FCF
240.06x
EV/EBITDA
50.79x
Shares Out
79.0M
Financials (TTM)
Revenue
$840.8M
Net Income
$80.7M
EBITDA
$112.1M
Free Cash Flow
$25.4M
Op Cash Flow
$25.7M
EPS Basic
$0.80
EPS Diluted
$0.98
EPS Forward
$1.36
Gross Margin
54.5%
Op Margin
11.9%
Net Margin
9.6%
Balance Sheet
Total Assets
$763.6M
Total Liab.
$196.0M
Total Equity
$567.6M
Cash
$414.1M
LT Debt
$6.5M
Book Value/Sh
$7.65
Debt/Equity
0.02x
Current Ratio
3.79
Quick Ratio
3.39
Returns & Growth
ROE
12.1%
ROA
8.8%
ROIC
8.2%
Rev Growth YoY
+60.1%
EPS Growth YoY
+233.3%
Price Returns
2W
-4.0%
1M
-4.4%
3M
+35.2%
6M
+69.3%
12M
+118.1%
Technicals
52W High
$82.94
52W Low
$35.20
50d MA
$74.06
200d MA
$54.28
RSI (14)
47.60
ATR (14)
$2.47
Beta
0.06
Avg Volume
495K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$64.00
High
$71.00
Low
$59.00
Median
$62.00
Data updated apr 25, 2026 5:46pm
· Source: financialmodelingprep.com